Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

No trades
See on Supercharts

Key facts today

Vertex Pharmaceuticals reported Q3 earnings of $4.38 per share, up from $4.08. Product revenue increased 12% to $2.77 billion. The company raised its 2024 revenue forecast to $10.8-$10.9 billion.
Vertex Pharmaceuticals is scheduled to report its earnings after the market close.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪121.60 B‬USD
−1.89USD
‪3.62 B‬USD
‪9.84 B‬USD
‪257.44 M‬
Beta (1Y)
0.94
Employees (FY)
‪5.4 K‬
Change (1Y)
+600 +12.50%
Revenue / Employee (1Y)
‪1.82 M‬USD
Net income / Employee (1Y)
‪670.30 K‬USD

About Vertex Pharmaceuticals Incorporated


CEO
Reshma Kewalramani
Headquarters
Boston
Website
Founded
1989
FIGI
BBG000C1S2X2
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VRTX is 472.80 USD — it has decreased by −0.06% in the past 24 hours. Watch Vertex Pharmaceuticals Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vertex Pharmaceuticals Incorporated stocks are traded under the ticker VRTX.
VRTX stock has fallen by −1.49% compared to the previous week, the month change is a 3.49% rise, over the last year Vertex Pharmaceuticals Incorporated has showed a 24.54% increase.
We've gathered analysts' opinions on Vertex Pharmaceuticals Incorporated future price: according to them, VRTX price has a max estimate of 600.00 USD and a min estimate of 325.00 USD. Watch VRTX chart and read a more detailed Vertex Pharmaceuticals Incorporated stock forecast: see what analysts think of Vertex Pharmaceuticals Incorporated and suggest that you do with its stocks.
VRTX reached its all-time high on Aug 1, 2024 with the price of 510.64 USD, and its all-time low was 3.25 USD and was reached on Feb 24, 1993. View more price dynamics on VRTX chart.
See other stocks reaching their highest and lowest prices.
VRTX stock is 1.43% volatile and has beta coefficient of 0.94. Track Vertex Pharmaceuticals Incorporated stock price on the chart and check out the list of the most volatile stocks — is Vertex Pharmaceuticals Incorporated there?
Today Vertex Pharmaceuticals Incorporated has the market capitalization of ‪122.03 B‬, it has increased by 0.67% over the last week.
Yes, you can track Vertex Pharmaceuticals Incorporated financials in yearly and quarterly reports right on TradingView.
Vertex Pharmaceuticals Incorporated is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
VRTX earnings for the last quarter are 4.38 USD per share, whereas the estimation was 4.08 USD resulting in a 7.41% surprise. The estimated earnings for the next quarter are 4.03 USD per share. See more details about Vertex Pharmaceuticals Incorporated earnings.
Vertex Pharmaceuticals Incorporated revenue for the last quarter amounts to ‪2.77 B‬ USD, despite the estimated figure of ‪2.69 B‬ USD. In the next quarter, revenue is expected to reach ‪2.76 B‬ USD.
VRTX net income for the last quarter is ‪1.05 B‬ USD, while the quarter before that showed ‪−3.59 B‬ USD of net income which accounts for 129.09% change. Track more Vertex Pharmaceuticals Incorporated financial stats to get the full picture.
No, VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has ‪5.40 K‬ employees. See our rating of the largest employees — is Vertex Pharmaceuticals Incorporated on this list?
Like other stocks, VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vertex Pharmaceuticals Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vertex Pharmaceuticals Incorporated technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vertex Pharmaceuticals Incorporated stock shows the buy signal. See more of Vertex Pharmaceuticals Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.